Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

Relapse after HSCT 2021 | Management of relapse post-alloHSCT in patients with B-cell lymphoma

Peter Dreger • 5 Oct 2021
Relapse after HSCT 2021
B-Cell Lymphoma Diffuse Large B-Cell Lymphoma Follicular Lymphoma Lymphoma

Peter Dreger, MD, Heidelberg University Hospital, Heidelberg, Germany, discusses treatment strategies that can be used in patients with B-cell lymphomas relapsing following allogeneic hematopoietic stem cell transplantation (alloHSCT). Prof. Dreger describes how radiotherapy alone or in combination with pathway inhibitors is an option for patients with aggressive B-cell lymphomas and large B-cell lymphomas that are insensitive to immunotherapy. He also comments on how biopsies can help identify druggable targets and how patients with other B-cell lymphomas, such as follicular lymphoma, can benefit from immunotherapy. This interview took place at the 2021 Relapse After HSCT² Workshop in New York, NY.

More from Peter Dreger

1:51
Challenges of CAR-T therapy for CLL
Peter Dreger • 5 Oct 2021
1:33
Management of relapse after CAR-T in patients with B-cell lymphoma
Peter Dreger • 5 Oct 2021
1:21
The role of transplant in the era of new treatments for lymphoma and CLL
Peter Dreger • 18 Apr 2016

Related Videos

3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals